In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2

Cancer Gene Therapy

Volumn 4, Issue 6, 1997, Pages 366-376

  Nagashima, Shigeki ^a,b   Reichert, Torsten E ^a,b   Kashii, Yoshiro ^a,b   Suminami, Yoshinori ^a,b   Chikamatsu, Kazuaki ^a,b   Whiteside, Theresa L ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Effector cells; IL 2 gene; IL 2 production; SCCHN; Tumor regression

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN DERIVATIVE; MESSENGER RNA; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; CELL LINE; CYTOTOXICITY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; KINETICS; METHODOLOGY; MOUSE; NATURAL KILLER CELL; NUDE MOUSE; PATHOLOGY; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-2; INTERLEUKINS; KILLER CELLS, NATURAL; KINETICS; MICE; MICE, NUDE; RECOMBINANT PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031267324     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993;53:5654-5662.
2. Clayman GL, Liu FJ, Savage HE, et al. Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa. Arch Oto Head & Neck Surg. 1992;118:41-48.
3. Stoter G, Goey SH, Egermont AM, et al. Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek. Biotlierapy. 1990;2:261-265.
4. Rechtsmeier WJ, Koch WM, McGuire WP, Poole ME, Chang EH. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Oto Head & Neck Surg. 1990;116:1271-1277.
5. Mingari MC, Gerosa F, Carra G, et al. Human interleukin 2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature. 1984;312:641-643.
6. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 1993;73:5-8.
7. Vujanovic NL, Yasumura S, Hirabayashi H, Lin W-C, Watkins S, Herberman RB, Whiteside TL. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol. 1995;154:281-289.
8. Lotze MT. Interleukin-2: basic principles. In: De Vita V, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer. Philadelphia, Penn: Lippincott; 1991:123-129.
9. Lin W-C, Yasumura S, Suminami Y, Sung M-W, Nagashima S, Stanson J, Whiteside TL. Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth. J Immunol. 1995; 155: 4805-4816.
10. Weidmann E, Sacchi M, Plaisance S, et al. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res. 1992;52:5963-5970.
11. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474-485.
12. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin 2 alone or in conjunction with lymphokine-activated killer cells for treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622-627.
13. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high-dose interleukin 2 alone. N Engl J Med. 1987;316:889-894.
14. Foa R, Guarini A, Cignetti A, Cronin K, Rosenthal F, Gansbacher B. Cytokine gene therapy: a new strategy for the management of cancer patients. Nat Immun. 1994;13: 65-75.
15. Culver KW. Clinical applications of gene therapy for cancer. Clin Chem. 1994;40:510-512.
16. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
17. Tsai S-CJ, Gansbacher B, Tait L, Miller FR, Heppner GH. Induction of antitumor immunity by interleukin-2 genetransduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst. 1993;85:546-553.
18. Haddada H, Ragot T, Cordier L, Duffour MT, Perricaudet M. Adenoviral interleukin-2 gene transfer into P 815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Human Gene Ther. 1993;4:703-711.
19. Zier KS, Salvadori S, Cronin KC, Gansbacher B. Vaccination with IL-2-secreting tumor cells stimulates the generation of IL-2-responsive T-cells and prevents the development of unresponsiveness. Cancer Gene Ther. 1994;1:43-50
20. Cignetti A, Guarini A, Carbone A, et al. Transduction of the IL-2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL-2 receptor expression. J Natl Cancer I. 1994;86:785-791.
21. Abdel-Wahab Z, W-P Li, Osanto S, et al. Transduction of human melanoma cells with interleukin-2 gene reduced tumorigenicity and enhances host antitumor immunity: a nude mouse model. Cell Immunol. 1994;159:26-39.
22. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci USA. 1995;92:8522-8526.
23. Vieweg J, Boczkowski D, Roberson KM, et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 1995;55:2366-2372.
24. Heo DS, Whiteside TL, Johnson JT, Chen K, Barnes EL, Herberman RB. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes (TIL) from human squamous cell carcinomas of the head and neck. Cancer Res. 1987;47:6353-6362.
25. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392-8396.
26. Zitovogel L, Tahara H, Cai Q, et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Human Gene Ther. 1994;5:1493-1506.
27. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
28. Friberg D, Bryant J, Shannon W, Whiteside TL. In vitro cytokine production by normal human peripheral blood mononuclear cells as a measure of immunocompetence or the state of activation. Clin Diagn Lab Immunol 1994;1:261-268.
29. Angelotti TP, Uhler MD, MacDonald RL. Assembly of GABAA receptor subunits: analysis of transient single-cell expression utilizing a fluorescent substrate/marker gene technique. J Neurosci. 1993;13:1418-1428.
30. Chen K, Demetris AJ, Van Thiel DH, Whiteside TL. Double immunoenzyme staining method for analysis of tissue and blood lymphocyte subsets with monoclonal antibodies. Lab Invest. 1987;56:114-119.
31. Suminami Y, Elder EM, Lotze MT, Whiteside TL. In situ interleukin-4 gene expression in cancer patients treated with genetically modified tumor vaccine. J Immunother. 1995;17:238-248.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation in cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
33. Vujanovic NL, Nagashima S, Herberman RB, Whiteside TL. Non-secretory apoptotic killing by human natural killer cells. J Immunol. 1996;157:1117-1126.
34. Vujanovic NL, Rabinowich H, Lee YJ, Jost L, Herberman RH, Whiteside TL. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic. Cell Immunol. 1993;151:133-157.
35. Whiteside TL, Bryant J, Day R, Herberman RB. Natural killer cytoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal. 1990;4: 102-114.
36. Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Method. 1991;145: 185-192.
37. Heo DS, Park J-G, Hata K, Day R, Herberman RB, Whiteside TL. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res. 1990;50:3681-3690.
38. Sacchi M, Snyderman CH, Heo DS, et al. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2. Cancer Res. 1990;50:3113-3118.
39. Vujanovic NL, Nagashima S, Giorda R, Herberman RB, Whiteside TL. Multiple mechanisms of killing of tumor cell targets by IL-2-activated natural killer cells. The 9th International Congress of Immunology. 1995;A293. Abstract.
40. Yasumura S, Lin W-C, Weidmann E, Hebda P, Whiteside TL. Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int J Cancer. 1994;59:225-234.
41. Gunji Y, Tagawa M, Matsubara H, et al. Murine colon carcinoma cells engineered to produce human interleukin-2 induce tumor-specific anti-tumor response. Int J Cancer. 1996;66:135-139.
42. Whiteside TL. Tumor Infiltrating Lymphocytes in Human Malignancies. Austin, Texas: R.G. Landes Co; 1993.